Meta-analysis: anticholinergics, but not beta-agonists, reduce severe exacerbations and respiratory mortality in COPD.
about
Tiotropium versus ipratropium bromide for chronic obstructive pulmonary diseaseLong-acting beta 2 -agonists and long-acting muscarinic antagonists in a combined inhaler versus either agent alone or placebo for chronic obstructive pulmonary diseaseTiotropium versus ipratropium bromide for chronic obstructive pulmonary diseaseTiotropium versus ipratropium bromide for chronic obstructive pulmonary diseaseOverview of the pharmacological challenges facing physicians in the management of patients with concomitant cardiovascular disease and chronic obstructive pulmonary diseaseAcute lung failureβ₂-Adrenergic agonists augment air pollution-induced IL-6 release and thrombosisCopd.Bridging differences in outcomes of pharmacoepidemiological studies: design and first results of the PROTECT projectEmergency hospital admissions after income-based deductibles and prescription copayments in older users of inhaled medications.Efficacy and safety of inhaled formoterol 4.5 and 9 μg twice daily in Japanese and European COPD patients: phase III study resultsShould we avoid beta-agonists for moderate and severe chronic obstructive pulmonary disease? YES.Long-acting Inhaled Bronchodilator and Risk of Vascular Events in Patients With Chronic Obstructive Pulmonary Disease in Taiwan PopulationImproved outcomes in patients with chronic obstructive pulmonary disease treated with salmeterol compared with placebo/usual therapy: results of a meta-analysis.Mortality in COPD: inevitable or preventable? Insights from the cardiovascular arena.Long-acting beta-agonists reduce mortality of patients with severe and very severe chronic obstructive pulmonary disease: a propensity score matching study.Inhaled anticholinergic use and all-cause mortality among elderly Medicare beneficiaries with chronic obstructive pulmonary disease.Targeting systemic inflammation: novel therapies for the treatment of chronic obstructive pulmonary disease.Bronchodilators in COPD: impact of beta-agonists and anticholinergics on severe exacerbations and mortality.The development of anticholinergics in the management of COPD.Role of tiotropium in the treatment of COPD.Role of arformoterol in the management of COPDLong-acting beta2-agonists (LABA) in chronic obstructive pulmonary disease: efficacy and safetyGuidelines for diagnosis and management of chronic obstructive pulmonary disease: Joint ICS/NCCP (I) recommendations.Exacerbation rate, health status and mortality in COPD--a review of potential interventionsA systematic review of the cardiovascular risk of inhaled anticholinergics in patients with COPD.One-year mortality associated with COPD treatment: a comparison of tiotropium and long-acting beta2-agonists in three Italian regions: results from the OUTPUL study.The small heat shock-related protein, HSP20, is a cAMP-dependent protein kinase substrate that is involved in airway smooth muscle relaxation.Cardiovascular mortality and morbidity in chronic obstructive pulmonary disease: the impact of bronchodilator treatment.Long-acting beta-agonists in the management of chronic obstructive pulmonary disease: current and future agents.Pharmacological treatment of COPD.Synthesis, grading, and presentation of evidence in guidelines: article 7 in Integrating and coordinating efforts in COPD guideline development. An official ATS/ERS workshop report.The safety of anticholinergic bronchodilators for the treatment of chronic obstructive pulmonary disease.Risk of Cardiovascular and Cerebrovascular Events in COPD Patients Treated With Long-Acting β2-Agonist Combined With a Long-Acting Muscarinic or Inhaled Corticosteroid.Clinical efficacy and safety of the combination of ipratropium bromide and fenoterol inhaled via the Respimat Soft Mist inhaler for relief of airflow obstruction.Rebuttal: should we avoid beta-agonists for moderate and severe chronic obstructive pulmonary disease? Yes.Rebuttal: should we avoid beta-agonists for moderate and severe chronic obstructive pulmonary disease? No.Should we avoid beta-agonists for moderate and severe chronic obstructive pulmonary disease? NOTime to question long-term safety of routine scheduled inhaled beta-2-agonist treatment for COPD.Effects of anticholinergics and beta-agonists in COPD.
P2860
Q24187073-004BC4B7-0ABF-413A-8DC3-20CA84280517Q24194044-349512B7-2ABD-4EEA-AD83-2FB0AC15FE42Q24198068-9D95655C-2914-41A0-A64D-BC9CBC57D49AQ24204005-1A81074A-F776-4A7E-938E-D701CFC0709BQ26741051-9165EA20-72AF-4153-BCDA-DE4D68D8418EQ26852173-73F91759-DED9-400A-AC12-1F0BD4E58372Q30581666-A944AC97-DF13-4019-820D-3C397CF0C171Q31016356-21D1D7B8-8262-4180-B37E-D50BB396C7ECQ33851671-05491D27-A871-4308-9203-711346C2BEDBQ34001895-AD98B2CE-28DE-46A7-8391-3D88F0A876B7Q34074832-B2B72A14-A2D7-4A80-8BD1-330815319ADFQ34688018-6C33CF9D-596E-4334-9770-5921E340B493Q36421017-C69E7247-7D52-46F4-9A6A-49B96A750026Q36695412-44C99554-3A45-4B12-88D4-2A7BB14AEE18Q36742804-B88DE0AA-AD4A-4BCC-9A61-048C9075049CQ36908742-AC3510C8-BC86-450E-8486-6643A7082927Q36929739-161EDD7E-7A11-484B-BB79-94AE50277CA1Q36956720-4923357C-81D2-40D9-B2D1-1C3E02615010Q37017238-A3357802-4A47-4DB6-A8EA-28C79D74F7DAQ37017248-CD0478D3-349F-4A1C-B394-499714359074Q37017516-66A9D5C2-49F1-4AB1-A9A9-F1BC44DAC090Q37070335-54614989-E837-46D5-9A62-A4BD61C09590Q37115933-40EB7071-08FC-44E9-92A3-6843AA40152CQ37177278-6294F118-4AE3-49DC-9D25-20C275F23B63Q37236165-64B7C3AB-D1F2-4461-9207-88625F231EECQ37284894-130F0402-6EEB-472E-84DE-D9A5A73D1B39Q37343961-4C7B0138-21DB-423D-816F-8C59C987B59DQ37377529-358FC6F5-DA60-4A45-A102-007E996F9C0FQ37619664-22F6CE49-6F38-4B07-BEFA-11491C39656DQ37804908-F5494DA2-481A-4D8D-BF8C-4862CAB7D2AEQ37924598-04D90CD6-45A9-4804-9156-EA51F1B3654CQ38068887-210CD218-4756-4D02-918F-6EDA49AC17AEQ38592062-E4AA1970-7738-4E1C-B6CC-4F89240FA016Q38693424-F57C5921-806E-4A24-BF68-ADDBD8E58B10Q39324466-AC7D4BE4-D0FA-4B60-BB02-B549D7BF3940Q41878771-F193E6EC-68C0-40EE-8243-F3C869F4F2A8Q41954093-7C09DDD2-8908-497C-94E3-DCDD0EC6F685Q42414640-056B1C06-7086-48AC-BBF0-3687B510914AQ42908603-7AC9887F-2E2A-4F42-BB7C-331D4FC45159Q42988199-EC9DFC5E-5AF3-46C1-97BA-C540AE63D1FC
P2860
Meta-analysis: anticholinergics, but not beta-agonists, reduce severe exacerbations and respiratory mortality in COPD.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Meta-analysis: anticholinergic ...... respiratory mortality in COPD.
@ast
Meta-analysis: anticholinergic ...... respiratory mortality in COPD.
@en
type
label
Meta-analysis: anticholinergic ...... respiratory mortality in COPD.
@ast
Meta-analysis: anticholinergic ...... respiratory mortality in COPD.
@en
prefLabel
Meta-analysis: anticholinergic ...... respiratory mortality in COPD.
@ast
Meta-analysis: anticholinergic ...... respiratory mortality in COPD.
@en
P2093
P2860
P1476
Meta-analysis: anticholinergic ...... respiratory mortality in COPD.
@en
P2093
Edwin E Salpeter
Nicholas S Buckley
Shelley R Salpeter
P2860
P304
P356
10.1111/J.1525-1497.2006.00507.X
P577
2006-10-01T00:00:00Z
P5875
P6179
1030196607